Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00060255 · ClinicalTrials.gov registry record · Phase 2

High-Dose Chemotherapy, Total-Body Irradiation, and Autologous Stem Cell Transplantation or Bone Marrow Transplantation in Treating Patients With Hematologic Cancer or Solid Tumors

A Phase 2 study, sponsored by Roswell Park Cancer Institute.

Completed
Registry status
Phase 2
Development phase
451
Enrollment target

NCT00060255: Completed Phase 2 study, sponsored by Roswell Park Cancer Institute.

NCT00060255 is a Phase 2 study that has completed, run by Roswell Park Cancer Institute. The registered enrollment target is 451 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (239% higher). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00060255, a Phase 2 study, has completed, sponsored by Roswell Park Cancer Institute.

COMPLETED
Registry status
Phase 2
Development phase
451 participants
Enrollment target

Study Summary

RATIONALE: Radiation therapy uses high-energy x-rays to damage cancer cells. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with autologous stem cell transplantation or autologous bone marrow transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. PURPOSE: This phase II trial is studying how well eight different high-dose chemotherapy regimens with or without total-body irradiation followed by autologous stem cell transplantation or autologous bone marrow transplantation works in treating patients with hematologic malignancies or solid tumors.

Interventions

  • DRUG carboplatin
  • DRUG cyclophosphamide
  • DRUG etoposide
  • DRUG carmustine
  • DRUG busulfan

Trial Details

FieldValue
Enrollment Target 451 participants
Start Date 1991-12
Est. Completion 2013-02
Phase Phase 2
Roswell Park Cancer Institute

365 total trials

What the finished NCT00060255 record still lists

NCT00060255 is an interventional study that assigns participants to a tested intervention. The registered 451 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (239% higher).

The record links to 0 conditions, and to 5 interventions - of which carboplatin is the first listed.

NCT00060255 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00060255 about?

NCT00060255 is a clinical study titled "High-Dose Chemotherapy, Total-Body Irradiation, and Autologous Stem Cell Transplantation or Bone Marrow Transplantation in Treating Patients With Hematologic Cancer or Solid Tumors". RATIONALE: Radiation therapy uses high-energy x-rays to damage cancer cells. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with autologous stem cell transplantation or autologous bone marrow transplantation may al...

What is the current status of trial NCT00060255?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 451 participants. The study started on 1991-12. Estimated completion is 2013-02.

What interventions are being tested in trial NCT00060255?

The interventions under investigation include: carboplatin (DRUG), cyclophosphamide (DRUG), etoposide (DRUG), carmustine (DRUG), busulfan (DRUG).

Who is sponsoring clinical trial NCT00060255?

This trial is sponsored by Roswell Park Cancer Institute, which has 365 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00060255's enrollment target sits among peer trials

451 87th of 2000 higher than 1,914 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05676255 · 452 participants · Phase 2

    The Breast Cancer Survivors and Partners Online Research Together (SUPORT) Project

  • NCT05703178 · 452 participants · Phase 3

    Web-based Pain Coping Skills Training for Breast Cancer Survivors With AI-Associated Arthralgia

  • NCT00515060 · 450 participants

    Psychophysical Studies of Cancer Therapy Pain

  • NCT01257269 · 450 participants

    Genotype and Phenotype Correlation in Hereditary Thrombotic Thrombocytopenic Purpura (Upshaw-Schulman Syndrome)

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00060255, the US trial registry maintained by the National Library of Medicine. NCT00060255 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.